133 related articles for article (PubMed ID: 27825868)
1. Development of a Targeted anti-HER2 scFv Chimeric Peptide for Gene Delivery into HER2-Positive Breast Cancer Cells.
Cheraghi R; Nazari M; Alipour M; Majidi A; Hosseinkhani S
Int J Pharm; 2016 Dec; 515(1-2):632-643. PubMed ID: 27825868
[TBL] [Abstract][Full Text] [Related]
2. Low molecular weight polyethylenimine cross-linked by 2-hydroxypropyl-gamma-cyclodextrin coupled to peptide targeting HER2 as a gene delivery vector.
Huang H; Yu H; Tang G; Wang Q; Li J
Biomaterials; 2010 Mar; 31(7):1830-8. PubMed ID: 19942284
[TBL] [Abstract][Full Text] [Related]
3. ScFv-decorated PEG-PLA-based nanoparticles for enhanced siRNA delivery to Her2⁺ breast cancer.
Dou S; Yang XZ; Xiong MH; Sun CY; Yao YD; Zhu YH; Wang J
Adv Healthc Mater; 2014 Nov; 3(11):1792-803. PubMed ID: 24947820
[TBL] [Abstract][Full Text] [Related]
4. Development of a novel histone H1-based recombinant fusion peptide for targeted non-viral gene delivery.
Soltani F; Sankian M; Hatefi A; Ramezani M
Int J Pharm; 2013 Jan; 441(1-2):307-15. PubMed ID: 23200954
[TBL] [Abstract][Full Text] [Related]
5. [Targeted detecting HER2 expression with recombinant anti HER2 ScFv-GFP fusion antibody].
Gao G; Chen C; Yang Y; Yang H; Wang J; Zheng Y; Huang Q; Hu X
Sheng Wu Gong Cheng Xue Bao; 2012 Aug; 28(8):1002-14. PubMed ID: 23185900
[TBL] [Abstract][Full Text] [Related]
6. Magnetic nanocarriers for the specific delivery of siRNA: Contribution of breast cancer cells active targeting for down-regulation efficiency.
Bruniaux J; Allard-Vannier E; Aubrey N; Lakhrif Z; Ben Djemaa S; Eljack S; Marchais H; Hervé-Aubert K; Chourpa I; David S
Int J Pharm; 2019 Oct; 569():118572. PubMed ID: 31352052
[TBL] [Abstract][Full Text] [Related]
7. Single-chain antibody-mediated gene delivery into ErbB2-positive human breast cancer cells.
Li X; Stuckert P; Bosch I; Marks JD; Marasco WA
Cancer Gene Ther; 2001 Aug; 8(8):555-65. PubMed ID: 11571533
[TBL] [Abstract][Full Text] [Related]
8. Development of a ZHER3-Affibody-Targeted Nano-Vector for Gene Delivery to HER3-Overexpressed Breast Cancer Cells.
Nazari M; Zamani Koukhaloo S; Mousavi S; Minai-Tehrani A; Emamzadeh R; Cheraghi R
Macromol Biosci; 2019 Nov; 19(11):e1900159. PubMed ID: 31531954
[TBL] [Abstract][Full Text] [Related]
9. Anti-HER2 scFv-Directed Extracellular Vesicle-Mediated mRNA-Based Gene Delivery Inhibits Growth of HER2-Positive Human Breast Tumor Xenografts by Prodrug Activation.
Wang JH; Forterre AV; Zhao J; Frimannsson DO; Delcayre A; Antes TJ; Efron B; Jeffrey SS; Pegram MD; Matin AC
Mol Cancer Ther; 2018 May; 17(5):1133-1142. PubMed ID: 29483213
[TBL] [Abstract][Full Text] [Related]
10. Tumor-targeted gene delivery via anti-HER2 antibody (trastuzumab, Herceptin) conjugated polyethylenimine.
Chiu SJ; Ueno NT; Lee RJ
J Control Release; 2004 Jun; 97(2):357-69. PubMed ID: 15196762
[TBL] [Abstract][Full Text] [Related]
11. Cancer gene therapy mediated by RALA/plasmid DNA vectors: Nitrogen to phosphate groups ratio (N/P) as a tool for tunable transfection efficiency and apoptosis.
Neves AR; Sousa A; Faria R; Albuquerque T; Queiroz JA; Costa D
Colloids Surf B Biointerfaces; 2020 Jan; 185():110610. PubMed ID: 31711736
[TBL] [Abstract][Full Text] [Related]
12. A new vector for controllable expression of an anti-HER2/neu mini-antibody-barnase fusion protein in HEK 293T cells.
Glinka EM; Edelweiss EF; Sapozhnikov AM; Deyev SM
Gene; 2006 Jan; 366(1):97-103. PubMed ID: 16300908
[TBL] [Abstract][Full Text] [Related]
13. Targeted Ultrasound-Triggered Phase Transition Nanodroplets for Her2-Overexpressing Breast Cancer Diagnosis and Gene Transfection.
Gao D; Gao J; Xu M; Cao Z; Zhou L; Li Y; Xie X; Jiang Q; Wang W; Liu J
Mol Pharm; 2017 Apr; 14(4):984-998. PubMed ID: 28282145
[TBL] [Abstract][Full Text] [Related]
14. Targeted delivery of CXCR4-siRNA by scFv for HER2(+) breast cancer therapy.
Jiang K; Li J; Yin J; Ma Q; Yan B; Zhang X; Wang L; Wang L; Liu T; Zhang Y; Fan Q; Yang A; Qiu X; Ma B
Biomaterials; 2015 Aug; 59():77-87. PubMed ID: 25956853
[TBL] [Abstract][Full Text] [Related]
15. A physicochemical approach for predicting the effectiveness of peptide-based gene delivery systems for use in plasmid-based gene therapy.
Duguid JG; Li C; Shi M; Logan MJ; Alila H; Rolland A; Tomlinson E; Sparrow JT; Smith LC
Biophys J; 1998 Jun; 74(6):2802-14. PubMed ID: 9635734
[TBL] [Abstract][Full Text] [Related]
16. Plasmid DNA delivery into MDA-MB-453 cells mediated by recombinant Her-NLS fusion protein.
Jeyarajan S; Xavier J; Rao NM; Gopal V
Int J Nanomedicine; 2010 Oct; 5():725-33. PubMed ID: 21042418
[TBL] [Abstract][Full Text] [Related]
17. An intracellular anti-erbB-2 single-chain antibody is specifically cytotoxic to human breast carcinoma cells overexpressing erbB-2.
Wright M; Grim J; Deshane J; Kim M; Strong TV; Siegal GP; Curiel DT
Gene Ther; 1997 Apr; 4(4):317-22. PubMed ID: 9176517
[TBL] [Abstract][Full Text] [Related]
18. Design, engineering and preparation of a multi-domain fusion vector for gene delivery.
Sadeghian F; Hosseinkhani S; Alizadeh A; Hatefi A
Int J Pharm; 2012 May; 427(2):393-9. PubMed ID: 22342333
[TBL] [Abstract][Full Text] [Related]
19. A Biodegradable Polyethylenimine-Based Vector Modified by Trifunctional Peptide R18 for Enhancing Gene Transfection Efficiency In Vivo.
Hu J; Zhu M; Liu K; Fan H; Zhao W; Mao Y; Zhang Y
PLoS One; 2016; 11(12):e0166673. PubMed ID: 27935984
[TBL] [Abstract][Full Text] [Related]
20. Peptide-functionalized ZCIS QDs as fluorescent nanoprobe for targeted HER2-positive breast cancer cells imaging.
Michalska M; Florczak A; Dams-Kozlowska H; Gapinski J; Jurga S; Schneider R
Acta Biomater; 2016 Apr; 35():293-304. PubMed ID: 26850146
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
